CTOs on the Move

BioNTech

www.biontech.com

 
At BioNTech we understand that every cancer patient`s tumor is unique and therefore each patient`s treatment should be individualized. To pioneer the next generation of patient-specific immunotherapies, we have combined ground-breaking research with cutting-edge technologies to develop therapeutics for cancer and beyond. Our broad and synergistic suite of platforms, which include mRNA therapeutics, engineered cell therapies, antibodies and small molecule immunomodulators have been optimized for distinct modes of action, high precision targeting, high potency and efficacy. We are also developing in parallel our own state-of-the-art manufacturing processes to complement our drug development platforms. We were founded in 2008 in Mainz, ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.biontech.com
  • 40 Erie Street Suite 110
    Cambridge, CA USA 92121
  • Phone: 617.337.4701

Executives

Name Title Contact Details

Similar Companies

Reprocell

Reprocell is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioMotiv

BioMotiv is an accelerator company associated with The Harrington Project, a $340 million initiative centered at University Hospitals of Cleveland.

Talis Biomedical

Tactiva Therapeutics

Tactiva is an immuno-oncology company based in Buffalo, New York, utilizing an innovative, dual T cell receptor (TCR) approach to adoptive T cell therapy.

Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient`s unique cancer. The company`s clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient`s cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine`s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer.